SCHEDULE 13G: Foresite Capital and James Tananbaum Disclose 5.6% Passive Stake in Maze Therapeutics
Beneficial Ownership Report
Foresite Capital entities and James Tananbaum have filed a Schedule 13G, reporting a combined beneficial ownership of 5.6% of Maze Therapeutics, Inc.'s common stock as of January 31, 2025.
Summary
- Foresite Capital Fund IV, L.P. (FCF IV) beneficially owns 2,111,917 shares of Maze Therapeutics, Inc. Common Stock, representing 4.8% of the class.
- Foresite Capital Management IV, LLC (FCM IV), as the general partner of FCF IV, is deemed to have sole voting and dispositive power over the 2,111,917 shares, also representing 4.8% of the class.
- Foresite Capital Fund V, L.P. (FCF V) beneficially owns 345,191 shares of Maze Therapeutics, Inc. Common Stock, representing 0.8% of the class.
- Foresite Capital Management V, LLC (FCM V), as the general partner of FCF V, is deemed to have sole voting and dispositive power over the 345,191 shares, also representing 0.8% of the class.
- James Tananbaum, as the managing member of both FCM IV and FCM V, is deemed to have sole voting and dispositive power over an aggregate of 2,457,108 shares, which includes shares held by FCF IV (2,111,917 shares) and FCF V (345,191 shares).
- The total beneficial ownership by James Tananbaum represents 5.6% of Maze Therapeutics, Inc.'s Common Stock outstanding.
- The percentage of class is calculated based on 43,776,978 Common Stock outstanding of Maze Therapeutics, Inc. as of January 31, 2025, as reported in the Issuer's prospectus on Form 424(b)(4) filed on the same date.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective information to assess sentiment beyond neutrality.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Disclosure of a significant passive investor, potentially signaling confidence or a new major shareholder base.
Key Dates
| Date | Description |
|---|---|
| 01/31/2025 | Date of event which requires the filing of this statement, and the date as of which the number of outstanding shares was reported in the Issuer's prospectus on Form 424(b)(4). |
| 02/07/2025 | Date of filing of this Schedule 13G statement. |
Keywords
Maze Therapeutics, Foresite Capital, James Tananbaum, Schedule 13G, beneficial ownership, common stock, SEC filing, institutional investor, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.